KRAZATI + ERBITUX
Therapy
A combination of adagrasib (BMS) and cetuximab (Eli Lilly) used in KRAS G12C-mutant colorectal cancer.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and KRAZATI + ERBITUX. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where KRAZATI + ERBITUX is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal | KRAS
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for KRAZATI + ERBITUX.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering KRAZATI + ERBITUX for eligible patients.
Test
therascreen KRAS RGQ PCR Kit
Qiagen Manchester, Ltd. (Qiagen)
Method
PCR
Specimen
Tissue (FFPE)
1 approvalView test profile →